公开(公告)号：US20170037142A1

公开(公告)日：2017-02-09

申请号：US15182422

申请日：2016-06-14

Applicant: Neil H. Bander

Inventor： Neil H. Bander

IPC: C07K16/30 ,  A61K51/10 ,  A61K45/06 ,  A61K47/48

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6851 ,  A61K47/6869 ,  A61K51/1045 ,  A61K51/1072 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/3069 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56

Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

Abstract translation: 提供了修饰抗体或其抗原结合片段到人前列腺特异性膜抗原（PSMA）的细胞外结构域。 修饰的抗PSMA抗体或其抗原结合片段与其给定物种（例如人）的未修饰对应物相比，具有较少的免疫原性。 还公开了包含上述抗体，核酸，重组表达载体和用于制备此类抗体和片段的宿主细胞的药物组合物。 还提供了使用本发明的抗体来检测人类PSMA或在体外或体内烧伤或杀死表达PSMA的细胞例如表达PSMA的癌症或前列腺细胞的方法。

公开(公告)号：US10517969B2

公开(公告)日：2019-12-31

申请号：US12658881

申请日：2010-02-17

Applicant: Neil H. Bander ,  Joseph Osborne ,  Stanley J. Goldsmith ,  Shankar Vallabhajosula

Inventor： Neil H. Bander ,  Joseph Osborne ,  Stanley J. Goldsmith ,  Shankar Vallabhajosula

IPC: A61K49/00 ,  A61K51/10 ,  A61K51/08

Abstract: A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

公开(公告)号：US07514078B2

公开(公告)日：2009-04-07

申请号：US10449379

申请日：2003-05-30

Applicant: Neil H. Bander ,  Francis J. Carr ,  Anita Hamilton

Inventor： Neil H. Bander ,  Francis J. Carr ,  Anita Hamilton

IPC: A61K39/395 ,  C12P21/04 ,  C12P21/08 ,  C12N15/02 ,  C07K16/00 ,  C07H21/04

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6851 ,  A61K47/6869 ,  A61K51/1045 ,  A61K51/1072 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/3069 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56

Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

Abstract translation: 提供了修饰抗体或其抗原结合片段到人前列腺特异性膜抗原（PSMA）的细胞外结构域。 修饰的抗PSMA抗体或其抗原结合片段与其给定物种（例如人）的未修饰对应物相比，具有较少的免疫原性。 还公开了包含上述抗体，核酸，重组表达载体和用于制备此类抗体和片段的宿主细胞的药物组合物。 还提供了使用本发明的抗体来检测人类PSMA或在体外或体内烧伤或杀死表达PSMA的细胞例如表达PSMA的癌症或前列腺细胞的方法。

公开(公告)号：US07163680B2

公开(公告)日：2007-01-16

申请号：US09929546

申请日：2001-08-13

Applicant: Neil H. Bander

Inventor： Neil H. Bander

IPC: A61K39/395

CPC classification number: A61K47/48638 ,  A61K47/6869 ,  A61K47/6899 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/3069 ,  C07K2317/77 ,  G01N33/57434 ,  G01N2333/705

Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.

Abstract translation: 本发明涉及使用抗体或其结合部分，探针，配体或其它生物制剂，其可以识别前列腺特异性膜抗原的细胞外结构域或与前列腺特异性膜抗原结合并内化。 这些生物制剂可被标记并用于检测癌组织，特别是表达前列腺特异性膜抗原细胞外结构域的靠近或含有血管内皮细胞的癌组织。 标记的生物制剂也可用于检测正常，良性增生和癌性前列腺上皮细胞或其部分。 它们也可以单独使用或与有效消融或杀死这种细胞的物质结合，如用于前列腺癌或其他癌症的治疗。 还公开了四种杂交瘤细胞系，其各自产生识别正常，良性增生性和癌性前列腺上皮细胞或其部分的前列腺特异性膜抗原的细胞外结构域的单克隆抗体。

公开(公告)号：US5773292A

公开(公告)日：1998-06-30

申请号：US463500

申请日：1995-06-05

Applicant: Neil H. Bander

Inventor： Neil H. Bander

IPC: C12N15/09 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61K49/00 ,  A61K51/00 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/574 ,  C12N5/12 ,  G01N33/53

CPC classification number: G01N33/57434 ,  C07K16/28 ,  A61K38/00 ,  Y10S436/813 ,  Y10S530/827 ,  Y10S530/828 ,  Y10S530/834 ,  Y10S530/85 ,  Y10S530/861 ,  Y10S530/863

Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.

Abstract translation: 本发明涉及使用抗体或其结合部分或识别正常，良性，增生性和癌性前列腺上皮细胞或其部分的抗原的探针。 这些抗体或其结合部分或探针可以被标记并用于检测这样的细胞。 它们也可以单独使用或与有效消融或杀死这种细胞的物质结合，如前列腺癌的治疗。 还公开了产生识别正常，良性，增生性和癌性前列腺上皮细胞或其部分的抗原的单克隆抗体的杂交瘤细胞系。

公开(公告)号：US4935344A

公开(公告)日：1990-06-19

申请号：US837531

申请日：1986-03-07

Applicant: Neil H. Bander ,  Carlos Cordon-Cardo ,  Connie L. Finstad ,  Willet F. Whitmore ,  Myron R. Melamed ,  Herbert F. Oettgen ,  Lloyd J. Old

Inventor： Neil H. Bander ,  Carlos Cordon-Cardo ,  Connie L. Finstad ,  Willet F. Whitmore ,  Myron R. Melamed ,  Herbert F. Oettgen ,  Lloyd J. Old

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  Y10S436/817 ,  Y10S530/809 ,  Y10S530/864

Abstract: Antigenic profiles of renal carcinoma specimans developed with panels of monoclonal antibodies derived from several different tissues serve as useful clinical indicators for cancer type, cancer subset as well as histiogenesis and prognosis indicators.

Abstract translation: 由几种不同组织衍生的单克隆抗体片段开发的肾癌标本的抗原谱，可作为癌症类型，癌症亚型以及组织发生和预后指标的有用临床指标。

公开(公告)号：US20090280120A1

公开(公告)日：2009-11-12

申请号：US12371399

申请日：2009-02-13

Applicant: Neil H. Bander

Inventor： Neil H. Bander

IPC: A61K39/395 ,  A61P35/00

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6851 ,  A61K47/6869 ,  A61K51/1045 ,  A61K51/1072 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/3069 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56

Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

Abstract translation: 提供了修饰抗体或其抗原结合片段到人前列腺特异性膜抗原（PSMA）的细胞外结构域。 修饰的抗PSMA抗体或其抗原结合片段与其给定物种（例如人）的未修饰对应物相比，具有较少的免疫原性。 还公开了包含上述抗体，核酸，重组表达载体和用于制备此类抗体和片段的宿主细胞的药物组合物。 还提供了使用本发明的抗体来检测人类PSMA或在体外或体内烧伤或杀死表达PSMA的细胞例如表达PSMA的癌症或前列腺细胞的方法。

公开(公告)号：US06649163B1

公开(公告)日：2003-11-18

申请号：US09357707

申请日：1999-07-20

Applicant: Neil H. Bander

Inventor： Neil H. Bander

IPC: A61K39395

CPC classification number: A61K47/48638 ,  A61K47/6869 ,  A61K47/6899 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/3069 ,  C07K2317/77 ,  G01N33/57434 ,  G01N2333/705

Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.

公开(公告)号：US6136311A

公开(公告)日：2000-10-24

申请号：US895914

申请日：1997-07-17

Applicant: Neil H. Bander

Inventor： Neil H. Bander

IPC: A61P35/00 ,  C07K16/30 ,  C12P21/08 ,  G01N33/574 ,  A61K39/395 ,  C07K16/00

CPC classification number: A61K47/48638 ,  A61K47/48761 ,  B82Y5/00 ,  C07K16/3069 ,  G01N33/57434 ,  A61K2039/505 ,  C07K2317/77 ,  G01N2333/705

Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.

公开(公告)号：US6087098A

公开(公告)日：2000-07-11

申请号：US839698

申请日：1997-04-15

Applicant: James M. McKiernan ,  Ihor S. Sawczuk ,  Ralph Buttyan ,  Neil H. Bander

Inventor： James M. McKiernan ,  Ihor S. Sawczuk ,  Ralph Buttyan ,  Neil H. Bander

IPC: C12Q1/68 ,  C07H21/04 ,  C12P19/34

CPC classification number: C12Q1/6886 ,  C12Q2600/112

Abstract: This invention provides methods of (a) diagnosing; (b) determining the stage of; and (c) monitoring the effect of a therapeutic intervention for a renal cell carcinoma in a human subject which comprises detecting the expression of the MN gene. In one embodiment, the method is directed to detection of the renal cell carcinoma known as clear cell carcinoma. In another embodiment, the method is used as a peripheral blood assay. In another embodiment, the method is a polymerase chain reaction assay for amplifying and detecting the presence of the cDNA molecule encoding the MN protein.

Abstract translation: 本发明提供（a）诊断方法; （b）确定阶段; 以及（c）监测人类受试者中肾细胞癌的治疗干预的效果，其包括检测MN基因的表达。 在一个实施方案中，该方法涉及被称为透明细胞癌的肾细胞癌的检测。 在另一个实施方案中，该方法用作外周血测定法。 在另一个实施方案中，该方法是用于扩增和检测编码MN蛋白的cDNA分子的存在的聚合酶链反应测定。